Clinical Trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-20.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT06994650
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Enrollment 140 participants
Start Date 2025-08-13
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-26